"Okay," Jane chuckles.
But you would never have known that she was diagnosed with early-stage Alzheimer's more than four years ago.
"There were instances that we kind of thought were senior moments and they were happening way too often," Jim recalled.
Jane enrolled in a trial for the Alzheimer's drug aducanumab. Participants were given the drug once a month as an IV infusion. It's designed to attack amyloid protein, a biomarker of Alzheimer's.
"Used aducanumab as a monoclonal antibody to attach to amyloid protein in the brain and remove it," explained Mark Goldstein, MD, CPI, Principal Investigator at JEM Research Institute.